Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
about
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trialsMagnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesMagnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopyDiagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and SpaceAssessment set for evaluation of clinical outcomes in multiple sclerosis: psychometric properties.A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.Outcome Measures in Clinical Trials for Multiple Sclerosis.The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.The emerging role of MRI in multiple sclerosis and the new diagnostic criteria.Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectivesRandomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesClinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis.Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.One year changes in disability in multiple sclerosis: neurological examination compared with patient self reportGetting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups."Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosisDisentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered careMagnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force.More immunotherapy for multiple sclerosis.Hand function in multiple sclerosis: force coordination in manipulation tasks.The problem with health measurement.Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.The prognostic utility of MRI in clinically isolated syndrome: a literature review.The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.Secondary Progressive Multiple Sclerosis: Definition and Measurement.Heterogeneous depression trajectories in multiple sclerosis patientsMultiple sclerosis functional composite: impact of reference population and interpretation of changes.Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.Combinations of drugs.MS clinical trial design for the future.Investigational drug therapies of treatment of multiple sclerosis.Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.Towards a european network for multiple sclerosis trials (ENMST).Association between MRI parameters and the MS severity scale: a 12 year follow-up study.Dysphagia in multiple sclerosis - prevalence and prognostic factors.Patient reported outcomes in benign multiple sclerosis.
P2860
Q22241715-8CAF2C05-2E7F-4438-8A4B-57F2F3E2BBA5Q24288978-1780D506-A000-4195-B087-3F80F88473F9Q24800569-3002AA2D-A89A-4E9C-AB8B-4F0F537CBE48Q29030707-CBD099D4-2C65-414D-AF6E-EAFEFC5174FDQ30460601-CE382177-C387-4D05-99BF-2CA338E5865BQ30666585-56717DAA-A827-4B34-A655-001F889532F6Q31160866-3B8A977C-BAF0-4973-97D4-252127C2F08CQ34406601-ECE61EC1-B4A6-4C1D-A16B-69A7C59741EFQ34590306-8941255F-8119-4D9C-82B3-53EFEB97025DQ34593669-ECAF2205-B5DD-45C2-8262-A7F0EB6F5160Q35182733-1F45F098-1032-4EF5-8358-6F7E24748DA2Q35453326-B3323623-5A0C-4EC5-A067-2CBA16AE3D99Q35455055-BE400B18-5B88-4867-8A30-B8CB69999179Q35456042-0E5252EF-7776-41C0-9067-380C884D1598Q35472473-2D6661D4-9B16-42DD-8BF7-B8EAEF869C1EQ36310327-D5CA7767-3AA5-4ABB-B83B-544EF295BFECQ36317642-07A8D869-BE21-4EA0-82C5-A431BBEFA80DQ36318306-3A9C7786-4476-4650-A069-159D6627828AQ36776446-269EA778-87B2-4BA4-8374-646FF2379995Q36814514-23CF73C7-167E-480A-9B19-15145C08EAB1Q36887909-A4AB649F-2C98-4F8A-B504-BB6394435B7AQ36896700-F908A8E8-92AD-439E-A067-A6344DBC7ACDQ36994825-EDD09B8B-DDC5-4331-BA1E-A0C8F6E190F4Q37906272-B22FF133-8C12-4306-8660-68383AF6B32DQ38022219-84631C2E-6F3F-4E9E-9375-CADB573AE115Q38211996-B0BC6303-C038-4BD4-8643-596A305E9D6DQ38629185-986CD19B-16B3-4329-B00C-84FF30CA4C96Q38831720-B0E390B2-C407-4CDF-90D3-3A026C205586Q39373778-9C89B35B-254E-43D3-B914-636C5997D095Q40629841-4AABBD82-7F4E-422D-91D7-81B7259D3ACAQ40923758-D8BD83A1-7296-41C9-85C8-18BE0C069830Q40933997-E336408E-FFB0-4310-AF65-F21077A23DA9Q40934002-81D4A70F-F0D8-41B7-AF48-4412D663E6F7Q41622019-C0042735-DC39-4365-B067-2F5DE39DC624Q42659776-89D47340-AB07-47FD-946D-E936CF28D76CQ43910524-16D774D1-E92D-4AD4-A0C6-5FE70D3EC21DQ47332049-36963493-9D61-44B9-986E-AB104AEF6A66Q48647377-D8250405-002E-48B9-8F3C-A8654DE37CC5Q48656557-68A13E56-F72B-4690-A5EF-492D5A3B3D13Q48898396-687DABA5-8157-4803-B8ED-98BB98D46983
P2860
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@en
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@nl
type
label
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@en
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@nl
prefLabel
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@en
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@nl
P2093
P2860
P1476
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
@en
P2093
H F McFarland
J N Whitaker
S C Reingold
P2860
P356
10.1177/135245859500100107
P577
1995-04-01T00:00:00Z